Machine learning demonstrates 89.4% sensitivity and 88.8% specificity in glioblastoma cells, highlighting improved classification efficiency.
Glioblastoma (GBM) is the most aggressive primary brain tumour (WHO Grade IV), and its significant molecular heterogeneity poses challenges for diagnosis and treatment decisions. Although single-cell RNA sequencing (scRNA-seq) has greatly advanced our understanding of this diversity , reliance on manual cell annotation remains a key bottleneck. This study proposed a machine learning pipeline integrating feature selection (SelectKBest with ANOVA F-test) and a four-layer neural network to classify malignant cells in a dataset of 40,026 single cells (17,403 malignant, 22,623 non-malignant).The analysis employed ANOVA-based feature selection (SelectKBest with f_classif) to identify the top 30 most discriminative genes, including established markers (EGFR, MALAT1) and novel candidates. A four-layer neural network (128-64-32-1 architecture) was implemented using Keras, with standardized inputs and early stopping to prevent overfitting. The model demonstrated strong performance with 89.4% sensitivity for malignant cells and 88.8% specificity for non-malignant cells (overall accuracy=89.1%, ROC-AUC=0.93). Notably, the pipeline reduced manual annotation time by 92% while maintaining clinical-grade precision, though 11.9% of non-malignant cells were conservatively misclassified as malignant - likely reflecting transitional states in the tumor microenvironment.
No takes yet. Share an insight, caveat, or question.
Zitong Sun (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: